U.S. Markets closed
  • S&P 500

    4,704.54
    +15.87 (+0.34%)
     
  • Dow 30

    35,870.95
    -60.10 (-0.17%)
     
  • Nasdaq

    15,993.71
    +72.14 (+0.45%)
     
  • Russell 2000

    2,363.59
    -13.42 (-0.56%)
     
  • Gold

    1,861.20
    -0.20 (-0.01%)
     
  • Silver

    24.88
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1369
    -0.0006 (-0.0568%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • Vix

    17.59
    +0.48 (+2.81%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • USD/JPY

    114.3040
    +0.0520 (+0.0455%)
     
  • BTC-USD

    58,402.43
    +1,852.62 (+3.28%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • Nikkei 225

    29,683.09
    +84.43 (+0.29%)
     

Up Over 500% in the Last 5 Years, Can This Biotech Continue Its Hot Streak?

·3 min read
Up Over 500% in the Last 5 Years, Can This Biotech Continue Its Hot Streak?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

This is the mantra of biologic manufacturer Codexis (NASDAQ: CDXS), which produces optimized enzymes to enhance the yield of current chemistry methods by traditional pharmaceutical companies. It was so focused on this effort that 51% of its revenue in 2012 was derived from a research and development collaboration with Royal Dutch Shell. When the agreement was terminated in August 2012, Codexis saw its full-year revenue melt from $88.3 million in 2012 to $31.9 million in 2013.